Hematologic Neoplasms Clinical Trials

A listing of Hematologic Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 63 clinical trials
TRial to EvaluAte Tranexamic Acid Therapy in Thrombocytopenia

The purpose of this study is to test whether giving tranexamic acid to patients receiving treatment for blood cancers reduces the risk of bleeding or death, and the need for platelet

hematologic malignancy
tranexamic acid
cell transplantation
cancer
  • 682 views
  • 26 Sep, 2021
  • 28 locations
Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older Medically Infirm or Frail Patients With Blood Diseases

This phase II/III trial studies the best approach in improving quality of life and survival after a donor stem cell transplant in older, weak, or frail patients with blood diseases. Patients who have undergone a transplant often experience increases in disease and death. One approach, supportive and palliative care (SPC), …

cancer
hematologic disorders
cell transplantation
blood disorder
  • 3 views
  • 21 Sep, 2021
  • 12 locations
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent IDH inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who have received

hematologic malignancy
blast cells
IDH2
  • 0 views
  • 16 Sep, 2021
  • 47 locations
Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)

This study will evaluate the safety and efficacy of favezelimab in combination with pembrolizumab (MK-3475) in participants with hematological malignancies: classical Hodgkin

hematologic malignancy
cancer
mk-3475
hodgkin's disease
large b-cell lymphoma
  • 45 views
  • 26 Sep, 2021
  • 25 locations
VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Multiple Myeloma)

The purpose of the study is to identify doses and schedules of VOB560 and MIK665 that can be safely given and to learn if the combination can have possible benefits for patients with Non-Hodgkin lymphoma (NHL), Multiple Myeloma (MM) or Acute Myeloid Leukemia (AML). VOB560 and MIK665 are selective and …

refractory acute myeloid leukemia (aml)
leukemia
b-cell lymphoma
multiple myeloma
tumor cells
  • 0 views
  • 26 Sep, 2021
  • 4 locations
A Study of JNJ-75276617 in Participants With Acute Leukemia

The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of JNJ-75276617 in Part 1 (Dose Escalation) and to determine safety and tolerability at the RP2D(s) in Part 2 (Dose Expansion).

acute leukemia
direct bilirubin
hydroxyurea
serum bilirubin level
gilbert's syndrome
  • 0 views
  • 17 Sep, 2021
  • 27 locations
Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab

The purpose of this study is to compare the efficacy (rate of very good partial response [VGPR] or better as best response as defined by the International Myeloma Working Group [IMWG] criteria) of daratumumab subcutaneous (Dara-SC) in combination with carfilzomib and dexamethasone (Kd) with the efficacy of Kd in participants …

progressive disease
maintenance therapy
bisphosphonate
dexamethasone
daratumumab
  • 21 views
  • 15 Sep, 2021
  • 164 locations
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

The purpose of this study is to identify recommended Phase 2 doses (RP2Ds) for each treatment combination (between daratumumab plus talquetamab and teclistamab plus daratumumab with or without pomalidomide) and to characterize the safety of each RP2D for selected treatment combinations.

measurable disease
serum immunoglobulin a
daratumumab
proteasome inhibitor
human chorionic gonadotropin
  • 54 views
  • 18 Sep, 2021
  • 25 locations
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to identify the recommended Phase 2 regimen(s) (RP2R[s]) and schedule for the study treatment (Part 1) and to characterize the safety of the RP2R(s) for the study treatment (Part 2). The RP2R(s) will describe the combination doses and schedules of (tal+tec+dara) the treatment combinations …

refractory multiple myeloma
human chorionic gonadotropin
carfilzomib
bortezomib
lenalidomide
  • 0 views
  • 17 Sep, 2021
  • 14 locations
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

Background Certain blood cancers can be treated with blood or bone marrow transplants. Sometimes the donor cells attack the recipient's body, called graft-versus

hematologic malignancy
total body irradiation
allogeneic transplantation
colony stimulating factor
fludarabine
  • 0 views
  • 27 Sep, 2021
  • 2 locations